Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 11:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 16,852 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Respiratory Tract Disease Clear all
Completed Phase 3 Interventional Results available

Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study

NCT01018186
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Furoate/GW642444, Fluticasone propionate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
18
States / cities
Oxford, Alabama • Huntington Beach, California • Mission Viejo, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Oct 14, 2026, 11:47 PM EDT
Completed Phase 2 Interventional Results available

Relative Potency of Formoterol Novolizer® 12 µg Compared to Formoterol Aerolizer® 12 µg

NCT01256086
View directory record Official record
Conditions
Asthma
Interventions
Formatris 24µg, Formatris 12µg, Foradil P 24µg, Foradil P 12µg
Drug
Lead sponsor
MEDA Pharma GmbH & Co. KG
Industry
Eligibility
18 Years to 60 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Gainesville, Florida • Iowa City, Iowa • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 11, 2022 · Synced Oct 14, 2026, 11:47 PM EDT
Completed No phase listed Observational Results available

A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)

NCT05169424
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Trelegy Ellipta, Stiolto Respimat, Tiotropium + Olodaterol (5/5 mcg), Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)
Device · Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
9,117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
White Plains, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2023 · Synced Oct 14, 2026, 11:47 PM EDT
Completed Phase 2 Interventional Results available

Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer

NCT00642759
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
carboplatin, Nab-paclitaxel, Bevacizumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 14, 2026, 11:47 PM EDT
Completed Phase 1 Interventional

Midodrine in Hepatopulmonary Syndrome

NCT03600870
View directory record Official record
Conditions
Hepatopulmonary Syndrome (HPS)
Interventions
Midodrine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 14, 2026, 11:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects

NCT02169583
View directory record Official record
Conditions
Infections, Respiratory Tract
Interventions
GSK1325756 Solution, GSK1325756 Solution Matching Placebo, GSK1325756 Tablet, GSK1325756 Tablet Matching Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 14, 2026, 11:47 PM EDT
Terminated Phase 4 Interventional

Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury

NCT04397510
View directory record Official record
Conditions
Covid-19, ARDS, Human, Acute Lung Injury
Interventions
Heparin, 0.9% Sodium-chloride
Drug
Lead sponsor
Frederick Health
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 14, 2026, 11:47 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma

NCT01634113
View directory record Official record
Conditions
Asthma
Interventions
tiotropium-bromide, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
1 Year to 5 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
4
States / cities
Columbia, Missouri • Oklahoma City, Oklahoma • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2015 · Synced Oct 14, 2026, 11:47 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing the Clinical Equivalence of Two Mometasone Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

NCT01038427
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
Mometasone furoate 50 mcg/actuation nasal spray (Lek Pharmaceuticals), Mometasone furoate (Nasonex®) 50 mcg/actuation nasal spray, Placebo
Drug
Lead sponsor
Sandoz
Industry
Eligibility
12 Years and older
Enrollment
795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
Austin, Texas • Kerrville, Texas • Live Oak, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 14, 2026, 11:47 PM EDT
Completed Phase 2 Interventional Results available

GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis

NCT03865927
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Placebo Oral Tablet, GKT137831
Other · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years to 85 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Birmingham, Alabama • New Orleans, Louisiana • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 14, 2026, 11:47 PM EDT
Not yet recruiting Early Phase 1 Interventional

Trial of ctDNA of Guidance to Determine PostOperative Radiation Therapy

NCT06979661
View directory record Official record
Conditions
Lung Cancer, Non Small Cell Lung Cancer, Lung Cancer Recurrent
Interventions
Haystack™ ctDNA Assay
Diagnostic Test
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 90 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Oct 14, 2026, 11:47 PM EDT
Terminated Phase 3 Interventional

TELI TON - Telithromycin in Tonsillitis

NCT00315042
View directory record Official record
Conditions
Tonsillitis, Pharyngitis
Interventions
Telithromycin (HMR3647), Penicillin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Months to 13 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 3, 2009 · Synced Oct 14, 2026, 11:47 PM EDT
Completed Not applicable Interventional

Self-Help for Stress Related to COVID-19

NCT04762173
View directory record Official record
Conditions
Stress
Interventions
Online self-help intervention
Device
Lead sponsor
Penn State University
Other
Eligibility
18 Years and older
Enrollment
585 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Oct 14, 2026, 11:47 PM EDT
Terminated Phase 2 Interventional Results available

Multicenter Evaluation of Docetaxel, Gemcitabine, and Bevacizumab Combination Followed by Bevacizumab Alone in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT00378573
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
docetaxel, gemcitabine, bevacizumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 26, 2010 · Synced Oct 14, 2026, 11:47 PM EDT
Active, not recruiting Not applicable Interventional

Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies

NCT05370469
View directory record Official record
Conditions
Lung Cancer, EGFR Gene Mutation, EGFR, ALK Gene Mutation, RET Gene Mutation, MET Gene Mutation, KRAS Mutation-Related Tumors, BRAF, ROS1 Gene Mutation
Interventions
Sensus Smartwatch Application, RX Cap, Fitbit Sense, Surveys
Other · Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 14, 2026, 11:47 PM EDT
Enrolling by invitation Not applicable Interventional

Evaluating the Feasibility and Preliminary Effects of BE+

NCT07214441
View directory record Official record
Conditions
Lung Cancer (Non-Small Cell), Self-management Behavior, Physical Activity, Stress, Quality of Life, Resistance Training
Interventions
Breathe Easier+
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 14, 2026, 11:47 PM EDT
Terminated Phase 2 Interventional Results available

Tocilizumab for Patients With Cancer and COVID-19 Disease

NCT04370834
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Pneumonia, Pneumonitis, Severe Acute Respiratory Distress Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Tocilizumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Rockville, Maryland • Las Vegas, Nevada • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 14, 2026, 11:47 PM EDT
Completed Early Phase 1 Interventional Results available

Procalcitonin to Reduce Antibiotic Use in Pediatric Pneumonia

NCT04963764
View directory record Official record
Conditions
Pneumonia, Pediatric Respiratory Diseases, Antibiotic Use, Community-acquired Pneumonia
Interventions
Amoxicillin, Placebo
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
12 Months to 71 Months
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Chicago, Illinois • Cincinnati, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Oct 14, 2026, 11:47 PM EDT
Completed Phase 2 Interventional Results available

Study of Dexpramipexole Chronic Sinusitis With Nasal Polyps and Eosinophilia

NCT02217332
View directory record Official record
Conditions
Chronic Sinusitis With Nasal Polyps and Eosinophilia
Interventions
dexpramipexole
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
7
States / cities
Boca Raton, Florida • Baltimore, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Oct 14, 2026, 11:47 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Stellate Ganglion Block for COVID-19-Induced Olfactory Dysfunction

NCT05445921
View directory record Official record
Conditions
Anosmia, Hyposmia, Parosmia, Olfactory Disorder
Interventions
Stellate Ganglion Block
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 14, 2026, 11:47 PM EDT
Completed No phase listed Observational

Effects of CPAP Therapy on PTSD Symptoms

NCT02019914
View directory record Official record
Conditions
PTSD, Sleep, Obstructive Sleep Apnea, Quality of Life
Interventions
Not listed
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 14, 2026, 11:47 PM EDT
Terminated Phase 4 Interventional Results available

Dextromethorphan Pediatric Acute Cough Study

NCT02651116
View directory record Official record
Conditions
Cough
Interventions
Dextromethorphan Hydrobromide, Placebo, Cough recording device
Drug · Device
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 11 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
18
States / cities
DeLand, Florida • Orlando, Florida • Blackfoot, Idaho + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 14, 2026, 11:47 PM EDT
Completed Not applicable Interventional

A Study to Determine Preferences Towards Interface Products

NCT03948152
View directory record Official record
Conditions
Sleep Disorder; Breathing-Related
Interventions
Standard of Care, Mask Advice Tool
Other
Lead sponsor
Philips Respironics
Industry
Eligibility
21 Years to 85 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Kissimmee, Florida • Chevy Chase, Maryland • Youngstown, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 14, 2026, 11:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of Lactobacillus Rhamnosus GG Versus Placebo in Elderly Subjects Receiving Live Attenuated Influenza Vaccine

NCT01545349
View directory record Official record
Conditions
Healthy, Influenza
Interventions
Lactobacillus rhamnosus GG ATCC 53103 (LGG), Placebo, Live attenuated influenza vaccine
Biological
Lead sponsor
Patricia L. Hibberd
Other
Eligibility
65 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 14, 2026, 11:47 PM EDT